Pyrimidinyl-piperazines useful as D 3 /D 2 receptor ligands

Details Pyrimidinyl-piperazines useful as D 3 /D 2 receptor ligands Pyrimidinyl-piperazines useful as D 3 /D 2 receptor ligands

2011-01-25

2011-01-25

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252140, C544S122000, C544S295000

Reexamination Certificate

active

07875610

ABSTRACT:
The present invention relates to new dopamine D3and D2ligands of formula (I):wherein R1, R2 and Q are as described herein, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes for preparing the same, to compositions containing the same and to their use in the treatment and/or prevention of conditions which requires modulation of dopamine receptors.

REFERENCES:
patent: 4957921 (1990-09-01), Caprathe et al.
patent: 6919342 (2005-07-01), Haupt
patent: 0 431 580 (1995-03-01), None
patent: WO 99/67206 (1999-12-01), None
Ulrich, Chapter 4: Crystallization, Kirk-Othmer Encyclopedia of Chemical Technology, Aug. 2002.
Vippagunta et al., Cyrstalline Solids, Advanced Drug Delivery Reviews, 48, pp. 3-26, 2001.
West, Solid Solutions, Solid State Chemistry and its applications, pp. 358 & 365, 1988.
Le Foll, et al., PubMed Abstract (Expert Opin Investig Drugs, 16(1):45-57), Jan. 2007.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20th Edition, vol. 2, pp. 2050-2057, 1996.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20th Edition, vol. 2, pp. 1992-1996, 1996.
Schwartz et al., Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions, Brain Research Reviews 31 (2000) pp. 277-287.
Bézard et al., “Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function,”Nat. Med., 2003, 9(6):762-767.
Brunton et al. (eds.),Goodman and Gilman's The Pharmacological Basis of Therapeutics, 2005, 11th Edition, McGraw Hill, p. 462.
Creese et al., “Species variation in dopamine receptor binding,”Eur. J. Pharmacol., 1979, 60:55-66.
Greengrass and Bremner, “Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors,”Eur. J. Pharmacol., 1979, 55(3):323-326.
Guérémy et al., “2-Amino-6-chloro-4-(N-methylpiperazino)pyrimidines, inhibitors of spiroperidol binding,”J. Med. Chem., 1982, 25(12):1459-1465.
Heidbreder et al., “The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence,”Brain Res. Rev., 2005, 49:77-105.
Joyce, “Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs,”Pharmacol. Therap., 2001, 90:231-259.
Laszy et al., “Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats,”Psychopharmacol., 2005, 179(3):567-575.
Levant, “The D3 dopamine receptor: neurobiology and potential clinical relevance,”Pharmacol. Rev., 1997, 49(3):231-252.
Levant et al.,CNS Drugs, 1999, 12:391.
Levant and McCarson, “D(3) dopamine receptors in rat spinal cord: implications for sensory and motor function,”Neurosci. Lett., 2001, 303:9-12.
Pacher and Kecskeméti, “Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?”Curr. Pharm. Des., 2004, 10(20):2463-2475.
Pilla et al., “Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist,”Nature, 1999, 400:371-375.
Schwartz et al., “Dopamine D3 receptor: basic and clinical aspects,”Clin. Neuropharmacol., 1993, 16(4):295-314.
Schwartz et al., “Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions,”Brain Res. Rev., 2000, 31:277-287.
Sokoloff et al., “Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics,”Nature, 1990, 347:146-151.
Stahl,Essential Psychopharmacology. Neuroscientific Basis and Practical Applications, 2000, 2nd ed., p. 409, Cambridge University Press.
Stemp et al., “Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat,”J. Med. Chem., 2000, 43(9):1878-1885.
Wong and Van Tol, “Schizophrenia: from phenomenology to neurobiology,”Neurosci. Biobehav. Rev., 2003, 27(3):269-306.
http://www.fda.gov/medwatch/safety/2006/Sep—PIs/RisperdalConsta—PI.pdf.
http://www.fda.gov/medwatch/safety/2006/Aug—PIs/Zyprexa—PI.pdf.
Aiken, C., “Pramipexole in psychiatry. A systematic review of literature,”J. Clin Psychiatry. 68:1230-1237, 2007.
Burger's Medicinal Chemistry and Drug Discovery. vol. 1. Drug Discovery, 6th Edition. Wiley Interscience. Ed. Donald J. Abraham, ISBN 978-0-471-27090-4, Jan. 2003).
Di. Chiara, G., “Drug addiction as dopamine-dependent associative learning disorder,” 1999.Eur. J. Pharmacol. 375: 13-30.
Maj, J. et al, “Effect of antidepressant drugs administered repeatedly on the dopamine D3 receptors in the rat brain,”Eur. J. Pharmacol. 351:31-37, 1998.
Millan, M.J., Gressier, H., Brocco, M., 1997. “The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats,”Eur. J. Pharmacol. 321, R7-R9.
Papp, M., Wieronska, J., “Antidepressant-like activity of amisulpride in two animal models of depression,”J. Psychopharmacol, 14:46-52, 2000.
Russel, V.A., “Neurobiology of animal models of attention-deficit hyperactivity disorder,”J. Neurosci. Methods161:185-198, 2007.
Rogóz Z, Klodzińska A, Maj J. “Anxiolytic-like effect of nafadotride and PNU 99194A, dopamine D3 receptor antagonists in animal models,”Pol J Pharmacol. Nov.-Dec. 2000;52(6):459-62.
P. Seeman, “Brain dopamine receptors”Pharmacological Review, vol. 32 No. 3 1980, pp. 238.
Shalev U, Grimm JW, Shaham Y, 2002. “Neurobiology of relapse to heroin and cocaine seeking: a review.,”Pharmacol. Rev. 54 (1), 1-42.
Steiner H, Fuchs S, Accili D “D3 dopamine receptor-deficient mouse: evidence for reduced anxiety,”Physiol Behav. Dec. 31, 1997;63(1):137-41.
Thanos, P.K. et al., “The effects of two highly selective dopamine D3 receptor antagonists (SB-277011A and NGB-2904) on food selfadministration in a rodent model of obesity,”Pharmacol Biochem Behav. 89: 499-507, 2008.
van der Kooij, M.A, Glennon, J.C. “Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder,”Neuroscience and Biobehavioral Reviews31: 597-618, 2007.
Tada et al., “Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine,”Psychopharmacology(Berl), Oct. 2004, vol. 176(1); pp. 94-100.
Paul Willner, P. Anthony S. Hale, A.S. and Argyropoulos, S. “Dopaminergic mechanism of antidepressant action in depressed patients,”J. Affective Disorders86: 37-45, 2005.
Gyertyan, I. et al, “Effects of dopamine D3receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011,”Behavioural Phramacology, vol. 15(4), 2004, pp. 253-262.
Gyertyan, I. et al., “The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats,”Euro. Jour. of Pharmacology, vol. 572, 2007, pp. 171-174.

Affiliated with

Also associated with

Rating

Pyrimidinyl-piperazines useful as D 3 /D 2 receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrimidinyl-piperazines useful as D 3 /D 2 receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidinyl-piperazines useful as D 3 /D 2 receptor ligands will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2633473